- Home
- FLNG vs ELVN Comparison
FLNG vs ELVN Comparison
Compare FLNG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNG | ELVN |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLNG | ELVN |
|---|---|---|
| Price | $24.75 | $15.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $23.00 | ★ $41.00 |
| AVG Volume (30 Days) | 374.6K | ★ 804.7K |
| Earning Date | 02-03-2026 | 11-12-2025 |
| Dividend Yield | ★ 12.13% | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $351,034,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.85 | N/A |
| P/E Ratio | $13.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.46 | $13.30 |
| 52 Week High | $27.67 | $25.37 |
Technical Indicators
Market Signals| Indicator | FLNG | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 34.13 |
| Support Level | $24.14 | $15.88 |
| Resistance Level | $25.04 | $18.05 |
| Average True Range (ATR) | 0.41 | 1.15 |
| MACD | -0.06 | -0.19 |
| Stochastic Oscillator | 35.13 | 2.14 |
Price Performance
Historical ComparisonAbout FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.